Labetalol S.A.L.F.

Labetalol, the active ingredient in Labetalol S.A.L.F., is a alpha/beta blocker presented as a injectable solution for intravenous use. It treats hypertensive emergencies and severe hypertension in adult patients.\n\nGNH India supplies Labetalol S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide.

Labetalol is employed in the management of acute elevations of blood pressure within the cardiovascular disease spectrum.\n\nHypertensive emergency: rapid reduction of dangerously high blood pressure to prevent end‑organ damage.\nSevere hypertension: sustained control of markedly elevated arterial pressure.\nPregnancy‑induced hypertension: helps lower blood pressure safely during pregnancy when oral agents are unsuitable.

Labetalol may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Dizziness\n- Nausea\n- Headache\n- Fatigue\n\nSerious or Rare Side Effects:\n- Severe hypotension\n- Bronchospasm\n- Hepatic dysfunction\n- Allergic reaction, including anaphylaxis

When using Labetalol, clinicians should observe several safety measures.\n\nMonitor blood pressure: adjust infusion to avoid abrupt drops.\nAssess cardiac function: caution in patients with heart failure or conduction abnormalities.\nAvoid in bronchospastic disease: risk of bronchoconstriction.\nUse with caution in hepatic impairment: metabolism may be reduced.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Labetalol can interact with several drug classes, requiring attention to avoid adverse outcomes.\n\nMajor Interactions (Avoid):\n- Other alpha or beta blockers: additive hypotensive effect.\n- Calcium channel blockers: increased risk of severe hypotension.\n- Epinephrine: may diminish labetalol efficacy.\n- MAO inhibitors: potential for hypertensive crisis.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure‑lowering effect.\n- ACE inhibitors or ARBs: additive hypotensive effect.